Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer

Trial Profile

Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Zoptarelin doxorubicin (Primary) ; Doxorubicin
  • Indications Endometrial cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ZoptEC
  • Sponsors AEterna Zentaris Inc
  • Most Recent Events

    • 01 May 2017 Results published in an Aeterna Zentaris media release.
    • 01 May 2017 According to an Aeterna Zentaris media release, Based on results from this trial, the company has decided not to pursue regulatory approval for Zoptrex for the treatment of endometrial cancer and does not anticipate conducting clinical trials with respect to any other indications.
    • 01 May 2017 Primary endpoint (Overall Survival) has not been met, according to an Aeterna Zentaris media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top